Kymera Therapeutics Inc
KYMRHealthcare|Biotechnology|USA
$119.36
+0.34 (+0.28%)
Tangible Book
$18.73
Upcoming Data Readouts (5)
Dec 2026
Est. completion
P1Healthy Participants
First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
NCT07412288n=96
Jun 2027
Est. completion
P2Atopic Dermatitis
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015n=200
Dec 2027
Est. completion
P2Eosinophilic Asthma
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
NCT07323654n=264
Feb 2028
Est. completion
Dec 2028
Est. completion
P2Asthma (Diagnosis)
A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
NCT07677059n=264